Monoamine transporter
Family in Homo sapiens that 11 drugs act on.
- Drugs that act on it: 11
- Approved: 4
- In phases 1 to 3: 7
- Sponsors: 10
- Genes: 3
Who is on it, and how far along
Every drug ChEMBL records acting on SLC6A2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 11
Approved4
Phase 33
Phase 24
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Abbott Laboratories19%
- Ajenat Pharmaceuticals19%
- Bristol-Myers Squibb19%
- DOV Pharmaceutical, Inc.19%
- Euthymics BioScience, Inc.19%
- GSK19%
- NeuroSearch A/S19%
- Novartis Pharmaceuticals19%
- Otsuka Pharmaceutical19%
- Sumitomo Pharma19%
| MethamphetamineBoxed warning | Approved | Ajenat Pharmaceuticals | Small molecule | Inhibitor | 53 |
| Mazindol | Approved | Novartis Pharmaceuticals | Small molecule | Inhibitor | 0 |
| NomifensineWithdrawn | Approved | — | Small molecule | Inhibitor | 0 |
| SibutramineWithdrawn | Approved | Abbott Laboratories | Small molecule | Inhibitor | 0 |
| Centanafadine | Phase 3 | Otsuka Pharmaceutical | Small molecule | Inhibitor | 5 |
| Bicifadine | Phase 3 | DOV Pharmaceutical, Inc. | Small molecule | Inhibitor | 0 |
| Dasotraline | Phase 3 | Sumitomo Pharma | Small molecule | Inhibitor | 0 |
| Amitifadine | Phase 2 | Euthymics BioScience, Inc. | Small molecule | Inhibitor | 0 |
| Liafensine | Phase 2 | Bristol-Myers Squibb | Small molecule | Inhibitor | 0 |
| NS-2359 | Phase 2 | GSK | Small molecule | Inhibitor | 0 |
| Tesofensine | Phase 2 | NeuroSearch A/S | Small molecule | Inhibitor | 0 |
| Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension | Methamphetamine | Phase 4 | Not yet recruiting | Oregon Health and Science University | Nov 16, 2026 |
| Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions | Methamphetamine | Not applicable | Recruiting | Michael Incze | Nov 4, 2026 |
| Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During the Withdrawal-Rehabilitation Period of Methamphetamine Use Disorder | Methamphetamine | Not applicable | Not yet recruiting | The First Affiliated Hospital of Zhejiang Chinese Medical University | Oct 28, 2026 |
| Transcranial Magnetic Stimulation for Methamphetamine Use Disorder During Pregnancy | Methamphetamine | Not applicable | Not yet recruiting | University of Utah | Sep 30, 2026 |
| Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder | Methamphetamine | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | Sep 17, 2026 |
| Closed-loop tTIS Targeted of the Nac as an Intervention for MUD Patients | Methamphetamine | Not applicable | Not yet recruiting | Shanghai Mental Health Center | Sep 3, 2026 |
| Closed-loop TBS Targeting rPO for the Core Clinical Features of Methamphetamine Use Disorder | Methamphetamine | Not applicable | Active, not recruiting | Shanghai Mental Health Center | Aug 20, 2026 |
| Psilocybin for Methamphetamine Use Disorder | Methamphetamine | Phase 2 | Not yet recruiting | Peter Hendricks | Aug 19, 2026 |
| A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | Centanafadine | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | Aug 12, 2026 |
| A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | Centanafadine | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | Jul 28, 2025 |
| A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | Centanafadine | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | Jul 25, 2025 |
| Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients | Centanafadine | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | Apr 16, 2025 |
| A Long-term Trial of EB-1020 in Adult Patients With ADHD | Centanafadine | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | Apr 15, 2025 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363064, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets